Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic metabolic disease affecting adults and children worldwide. It has become one of the leading causes of death, as obesity is known to be the main risk factor for a number of non-communicable diseases, in particular type 2 diabetes. This close relationship led to the connotation ‘diabesity', highlighting the fact that the majority of individuals with diabetes are overweight or obese. Until today the BMI is still used to classify overweight and obesity. Since reduced muscle mass is highly prevalent throughout the BMI range, the measurement of body composition is strongly recommended. Moreover, it is essential for monitoring the course of weight reduction, which is part of every effective anti-obesity treatment. Weight reduction can be achieved via different weight loss strategies, including lifestyle intervention (diet and exercise), pharmacotherapy, or bariatric surgery. However, not all of these strategies are suitable for all patients, and any further needs should be considered. Besides, attention should also be drawn to concomitant therapies. These therapies may promote additional weight gain and further trigger the deterioration of blood glucose control. Thus, therapeutic strategies are warranted, which can be easily used for the management of obese patients with type 2 diabetes to achieve their glycemic and weight loss goals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
In the citing paper
“Obesity is the strongest risk factor for T2D and the obesity epidemic is heavily contributed to the rise of T2D prevalence, especially the increased rates of young-onset T2D [2].”
In the citing paper
“Obesity is the strongest risk factor for T2D and the obesity epidemic is heavily contributed to the rise of T2D prevalence, especially the increased rates of young-onset T2D [2].”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Self-citationGlobal burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
Shai, I., Schwarzfuchs, D., Henkin, Y., Shahar, D. R., Witkow, S., Greenberg, I., Golan, R., Fraser, D., Bolotin, A., Vardi, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708681 · Cited by 2,143
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Cited by
Items 401–430 of 430
Adipositas und Diabetes: Was kann man in der Praxis tun?
Weiner, S. R. (2025) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-025-5340-6
Campbell, E., Jia, H., Cassells, A. N., Lin, T., Lainez, J. C., Tobin, J. N., Smaldone, A. M., Desai, P. M., Hripcsak, G. M., & Mamykina, L. (2025) · medRxiv · doi:10.1101/2025.10.28.25338894
Wang, Q., Chen, P., Wei, W., Guo, J.-Y., Bao, Y.-Y., Zhang, J., & Yu, K. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005397
Common diseases associated with indoor air quality
Turner, A. M., & Ng, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26643-0.00009-1
Bagheripour, F., Jeddi, S., & Ghasemi, A. (2025) · Intern J Endocrinol Metab · doi:10.5812/ijem-162367
Zhang, Y., Ma, R., Ma, Y., & Zhou, R. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1680402 · Cited by 2
Nanomedicines for precise therapy in hyperlipidemia and obesity
Bhattamisra, S. K., Boddu, P., Kundu, A., Radha, G. V., Mondal, S., Rajkumar, J., Sahu, K., Singha, R., & Goswami, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00010-7
Shaheen, M. Y., Basudan, A. M., Al-Zawawi, A. S., AlAhmari, F., Al‐Shibani, N., Al‐Kattan, R., Alssum, L. R., Shaheen, F. A. Y., & Talakey, A. A. (2025) · Acta Odontologica Scandinavica · doi:10.2340/aos.v84.44957
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.25720305
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Abou-Samra, A. B., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714038
Bai, K., Chen, X., Song, R., Shi, W., & Shi, S. (2022) · Figshare · doi:10.6084/m9.figshare.20025035
Shams‐White, M., Tjaden, A. H., Edelstein, S. L., Bassiouni, S., Kahle, L., Kim, C., Pi-Sunyer, X., Temple, K. A., Venditti, E. M., Reedy, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21184194
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.25720119
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714032
Elashi, A. A., Toor, S. M., Umlai, U.-K. I., Al-Sarraj, Y. A., Taheri, S., Suhre, K., Samra, A. B. A., & Albagha, O. (2024) · Figshare · doi:10.6084/m9.figshare.26714044
ROS-Mediated Cellular Signaling in Metabolic Disorders
Mondal, M., Pramanik, S., Patel, Diwan, A., Samanta, R. K., Panja, S., Maity, A., & Pramanik, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-11752-6_1
From detection to intervention: nanotechnology-driven precision strategies in obesity management
Tantray, J., Khadam, V. K. R., Patel, A., Nagdev, S., & Prajapati, B. (2026) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-026-01397-9 · Cited by 1
“Since thyroid hormone was introduced as the first anti-obesity medicine in 1893, most have been abandoned due to side effects in obese people (Bray et al. 2018; Kennett and Clifton 2010; Leitner et al. 2017a, b).”
Time restricted EAting for Type 2 diabetes and MEtabolic health: The TEA TIME trial study protocol
Retnakaran, M., Lessa, V. L., & Kramer, C. K. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343494 · Cited by 1
“While lifestyle interventions that have achieved weight loss have been shown to improve insulin resistance [3,9], their impact on pancreatic beta-cell function is not fully understood.”
Marassi, M., Pollis, R. M., & Fadini, G. P. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104714
Akar, E. A. (2022) · theses.fr (ABES) · doi:10.70675/a7b15e3fz84e7z4915z9447zc112181e06e4
Chemogenetic manipulation of the hippocampus alleviates obesogenic diet-induced memory deficits
Bakoyiannis, I. (2021) · theses.fr (ABES) · doi:10.70675/f5ac23cezc829z4dc0zaf4az467fb1eb75a9
Yao, F., Gou, J., Zhu, X., Tang, K., & 刘朝辉 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819071
“Moreover, with rising obesity rates, changes in lifestyle habits, and increased life expectancy, the prevalence of diabetes is gradually increasing (6, 7).”
Lee, H. W., Kim, H. J., Park, J. S., Lee, J. H., Park, J. J., Gwon, M., Cho, J., Seong, S. J., & Yoon, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s574016 · Cited by 1
“9,10 Sodium-glucose cotransporter 2 (SGLT2) inhibitors, approved for the management of T2D, are associated with weight loss.”
Singh, H., Raj, D., & Singh, G. (2026) · British Food Journal · doi:10.1108/bfj-09-2025-1181
Malekpour, H., Zakipour, M., Taherpour, N., Mahjoob, M. P., & Sistanizad, M. (2026) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp-170975
Suvarna, C., Mohanty, I. R., Rai, S., & Khan, M. S. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00452
The Impact of Slow Energy Release Dietary Carbohydrates in Weight Management: A Mini-Review
Qi, X., & Tester, R. F. (2026) · Recent Progress in Nutrition · doi:10.21926/rpn.2603016
Dinler, E., DEMIRCI, T., Kocaağa, Ş., & Ekici, G. (2026) · Journal of Advanced Studies in Health Science and Obesity · doi:10.51271/jashso.30
Metadata
- Authors
- Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H.
- Affiliations
- University of Graz (AT)
- Instituto de Salud Carlos III (ES)
- Istanbul University-Cerrahpaşa (TR)
- Medical University of Vienna (AT)
- European Association for the Study of Obesity (GB)
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 10
- Issue
- 5
- Pages
- 483-492
- ISSN
- 1662-4025 (ISSN-L)
- 1662-4033
- PMC
- PMC5741209
- OpenAlex
- W2762120405
- Cited by
- 431
- References
- 76
- Citations by year
- 2026: 16 · 2025: 51 · 2024: 67 · 2023: 80 · 2022: 76 · 2021: 68 · 2020: 51 · 2019: 14 · 2018: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Obesity Facts (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- obesity, type 2 diabetes, diabesity, body composition, weight loss, lifestyle intervention, pharmacotherapy, bariatric surgery, glycemic control
- MeSH terms
- Adult, Child, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diet, Health Services Needs and Demand, Humans, Life Style, Obesity, Exercise, Comorbidity, Anti-Obesity Agents, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.